Cardiorenal Syndrome Type 4—Cardiovascular Disease in Patients with Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management by Pateinakis, Panagiotis & Papagianni, Aikaterini
SAGE-HindawiAccess to Research
International Journal of Nephrology
Volume 2011, Article ID 938651, 8 pages
doi:10.4061/2011/938651
Review Article
CardiorenalSyndrome Type 4—CardiovascularDiseasein
PatientswithChronicKidneyDisease:
Epidemiology, Pathogenesis,andManagement
PanagiotisPateinakisand AikateriniPapagianni
Department of Nephrology, Aristotle University of Thessaloniki, General Hospital of Thessaloniki “Hippokration”, Papanastasiou 50,
546 42 Thessaloniki, Greece
Correspondence should be addressed to Aikaterini Papagianni, aikpapag@otenet.gr
Received 30 August 2010; Accepted 3 January 2011
Academic Editor: Claudio Ronco
Copyright © 2011 P. Pateinakis and A. Papagianni. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The term cardiorenal syndrome refers to the interaction between the heart and the kidney in disease and encompassesﬁve distinct
types according to the initial site aﬀe c t e da n dt h ea c u t eo rc h r o n i cn a t u r eo ft h ei n j u r y .T y p e4 ,o rc h r o n i cr e n o c a r d i a cs y n d r o m e ,
involves the features of chronic renal disease (CKD) leading to cardiovascular injury. There is suﬃcient epidemiologic evidence
linking CKD with increased cardiovascular morbidity and mortality. The underlying pathophysiology goes beyond the highly
prevalent traditional cardiovascular risk burden aﬀecting renal patients. It involves CKD-related factors, which lead to cardiac and
vascular pathology, mainly left ventricular hypertrophy, myocardial ﬁbrosis, and vascular calciﬁcation. Risk management should
considerboth traditional and CKD-related factors, while therapeutic interventions,apart from appearing underutilized, still await
further conﬁrmationfrom large trials.
1.Introduction
Thetermcardiorenalsyndrome hasbeenintroducedrecently
in an attempt to emphasize the tight interaction between
the cardiovascular and renal systems in acute or chronic
disease settings and to expand our knowledge regarding its
pathogenesis, prevention, and potential treatment [1].
The deﬁnition encompasses diﬀerent syndromes, all
involving the heart and the kidney, “whereby acute or
chronic dysfunction of one organ may induce an acute or
chronic dysfunction of the other” [2]. According to the
site of the initial injury and the acute or chronic nature of
the process ﬁve distinct syndromes (types) are deﬁned. In
acute cardio-renal syndrome (Type 1), acute worsening of
heart function leads to acute renal dysfunction. In chronic
cardiorenal syndrome (Type 2), chronic cardiac dysfunction
leads to chronic renal dysfunction. In acute renocardiac
syndrome (Type 3), acute renal dysfunction causes cardiac
dysfunction, and in chronic renocardiac syndrome (Type
4), chronic renal dysfunction leads to cardiovascular disease
and increased cardiovascular mortality [1]. Finally, type
5, or secondary cardiorenal syndrome, involves systemic
conditions such as diabetes mellitus, amyloidosis, systemic
lupus erythematosus, or sepsis, which simultaneously aﬀect
both the heart and the kidney [2].
This paper will focus on cardiorenal syndrome type 4
(chronic renocardiac syndrome) presenting epidemiologic
evidence of excess cardiovascular morbidity and mortality
in patients with chronic kidney disease (CKD) as well as
current knowledge on the pathogenesis and management of
this syndrome.
2.EpidemiologicEvidenceLinking CKDand
CardiovascularDisease (CVD)
CKD is deﬁned as either a reduction in the glomerular
ﬁltration rate (GFR) to values below 60ml/min/1.73m2,o r
the presence of kidney damage as reﬂected in an abnor-
mal urine sediment (proteinuria, hematuria, and casts) or2 International Journal of Nephrology
abnormalities in renal architecture (e.g., polycystic kidney
disease) even if the GFR is preserved within normal levels.
GFR may be directly measured by renal clearance of speciﬁc
substances (e.g., creatinine, inulin) and radioactive markers
(e.g., 99mTc-DTPA) or it may be estimated (estimated GFR-
eGFR), by the application of formulas incorporating serum
creatinine and demographic parameters (Cockcroft-Gault,
MDRD) [3].
Both proteinuria and the reduction of GFR have been
associated with increased cardiovascular morbidity and
mortality [4]. This association is so strong and clinically
relevant that according to current guidelines the diagnosis
of CKD places a patient into the highest cardiovascular risk
level, irrespective of stratiﬁcation according to traditional
cardiovascular risk factors [3, 4]. Compared to the general
population, CKD patients are still plagued by a frustratingly
high mortality, which is mainly attributed to cardiovascular
events, with death being far more probable than advancing
into the ﬁnal CKD stages and the need of renal replacement
therapy (RRT) [5]. The high mortality aﬄicting patients on
renal RRT, which for the ages between 25 and 35 may rise
up to 375-fold compared to the general population [6], is
derived almost by half of cardiovascular causes [7].
2.1. Proteinuria/Albuminuria and CVD. The abnormal
quantities of protein in the urine (proteinuria) consist
mainly of albumin (albuminuria) and can be semiquan-
titatively identiﬁed by urine dipstick testing, estimated by
the urine protein-to-creatinine ratio (UPCR) or albumin-
to-creatinine ratio (UACR) in a spot urine sample, or
directly measured in a timed (usually 24h) urine col-
lection [3, 8]. The diagnosis of microalbuminuria (30–
300mg/day) and albuminuria (>300mg/day) is mainly
utilized in the evaluation of diabetic nephropathy, while
proteinuria (>300mg/day or UPCR >200mg/g) is mostly
used for nondiabetic CKD [8].
Whether considered a marker of systemic endothelial
dysfunction or a result of renal damage [9], proteinuria has
been associated with increased cardiovascular mortality in
the general population, even at levels regarded as normal
[10]. In repeated studies, the presence of micro- and
macroalbuminuria and eGFR reduction were independent
predictors of increased overall and cardiovascular mortality
in diabetic [11] and nondiabetic individuals [12]. In a
recently published large community-based study involving
nearly one million adult subjects, the presence of proteinuria
was assessed by urine dipstick or UACR. Higher levels of
proteinuria were independently associated with an increased
risk of myocardial infarction and all-cause mortality, as
were decreased levels of eGFR. The severity of proteinuria
was actually a stronger predictor of worse clinical outcomes
than was eGFR reduction, a fact suggesting that levels of
proteinuria may have a role in risk stratiﬁcation of CKD
patients, who are currently staged only according to their
level of GFR [13].
2.2. GFR and CVD. Irrespective of the presence of pro-
teinuria, GFR decline has been repeatedly associated with
increased cardiovascular morbidity and mortality. In a
large community study involving more than one million
adults, an independent and graded association was observed
between eGFR reduction and increased risk of death and
cardiovascular events including hospitalization for coronary
artery disease, heart failure, stroke, and peripheral vascular
disease [14]. In middle-aged adults participating in the
Atherosclerosis Risk in Community (ARIC) study, a baseline
eGFR of less than 60ml/min/1.73m2 was independently
associated with an increased risk of developing peripheral
arterial disease [15] or heart failure, irrespective of prevalent
coronary artery disease [16]. According to United States
Renal Data System 2007 annual report regarding incident
dialysis patients, comorbidities included congestive heart
failure in 34%, atherosclerotic heart disease in 22.5%,
cerebrovascular disease in 10%, and peripheral vascular
disease in 15% of cases [17].
2.3. Cardiovascular Outcomes in CKD. In patients with
already established cardiovascular disease, renal impair-
ment markedly worsens outcomes. An inverse relationship
between eGFR and the extent of coronary stenotic lesions
was shown [18], as well as increased probability of having
three-vessel coronary artery disease with decreasing eGFR
[19]. In a study of almost 15.000 patients, who had
suﬀered myocardial infarction, even mild eGFR reduction
at baseline was independently associated with increased
overall mortality or a composite end point of death from
cardiovascular causes, reinfarction, congestive heart failure,
stroke, or resuscitation after cardiac arrest [20]. In patients
undergoing coronary artery bypass grafting, a reduced
baseline eGFRhasalsobeenassociated withincreased 30-day
and long-term mortality [21]. Furthermore, in patients with
advanced congestive heart failure, impaired renal function
seems to be a stronger predictor of mortality than impaired
cardiac function (left ventricular ejection fraction and New
York Heart Association class) [22]. Finally, in a recent study
also involving patients with heart failure, the presence of
albuminuria signiﬁcantly aggravated prognosis by exhibiting
a strong and independent association with increased all-
cause and cardiovascular mortality [23].
3.CardiovascularInjury inCKD
Due to the vital importance for the rapidly growing
population of CKD patients, the pathogenetic mechanisms
leading to cardiovascular damage in renal disease are under
constant investigation. More than a dozen of pathways
have been identiﬁed including hyperactivity of the renin-
angiotensin-aldosterone system, osmotic sodium retention,
volume overload, endothelial dysfunction, dyslipidemia,
coagulopathy, inﬂammation, and anemia [24], all leading to
histomorphological alterations of the heart and vessels.
In addition, some key emerging topics in this ﬁeld
include sympathetic hyperactivity, cardiotonic steroids,
nonosmotic sodium retention, and catalytic or labile iron.
Sympathetic activation by the failing kidney leading to
both renal disease progression and cardiovascular morbidityInternational Journal of Nephrology 3
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Figure 1: Heart alterations and their consequences in CKD. AVF: arteriovenous ﬁstula, AngII: angiotensin II, ET-1: endothelin-1, LVH: left
ventricular hypertrophy, PTH: parathormone, RAAS: renin-angiotensin-aldosteronesystem, SNS: sympathetic nervous system.
and mortality may provide a new target for therapeutic
intervention [25]. Cardiotonic steroids are elevated in renal
failure and have been linked to hypertension and to the
development of uremic cardiomyopathy in animal models
[26]. Nonosmotic sodium stores in the form of water-
free Na+ accumulation in the skin have been proposed to
contribute to the development of hypertension and thus
might be associated to CKD progression and cardiovascular
complications [27]. Finally, labile/catalytic iron is associated
with oxidative stress in situations such as acute kidney
injury after cardiac revascularisation and in diseases such as
diabetes and may result in both kidney disease progression
and cardiovascular complications [28]. However, an exten-
sive analysis of all the above mechanisms lies outside the
scopus of the present paper, and readers are referred to some
excellent recent reviews [25–28].
3.1. The Heart in CKD. The mechanisms leading to cardiac
alterations in CKD are depicted in Figure 1. Cardiac work-
load is increased in CKD. This increase is the result of two
separate pathways both leading to left ventricular hypertro-
phy (LVH):pressure overload and volumeoverload. Pressure
overload mainly derives from increased peripheral resis-
tance and reduced arterial compliance due to sympathetic
and renin-angiotensin system hyperactivity, hypertension,
endothelialdysfunction, andvascularcalciﬁcation/stiﬀening.
It causes thickening of cardiac myoﬁbres by parallel addition
ofsarcomeres, thusleading to concentricLVH. Volume over-
loadisattributedtosodiumandwaterretention,anemia,and
the presence of an arteriovenous ﬁstula in patients with end-
stage renal disease (eGFR <15ml/min/1.73m2 anticipating
oronchronicdialysis).Itresultsin lengtheningofthecardiac
myoﬁbers by serial addition of sarcomeres thus causing
eccentric LVH (left ventricular dilatation) [29, 30]. LVH in
renal disease is a pathologic process and, unlike physiologic
adaptations to increased workload (e.g., “athletes heart”),
is accompanied by ﬁbrosis, which is also attributed to
conditions related to the uremic milieu, including increased
levels of parathyroid hormone, endothelin, aldosterone,
catecholamines, and cardiotonic steroids [26, 30, 31]. In a
study involving 432 ESRD patients, only 16% had a normal
echocardiogram at initiation of dialysis, the rest exhibiting
mainly featuresofconcentric LVH (41%)and left ventricular
dilatation(28%),bothassociated with increased risk ofheart
failure and death [32]. A more recent study demonstrated
progression of concentric LVH in 576 new dialysis patients
followed up by echocardiography [33].
In addition to ﬁbrosis and cardiomyocyte hypertrophy,
histological changes of the heart in uremia also include
myocyte apoptosis/necrosis resulting in myocyte number
reduction, and microvascular abnormalities such as arterio-
lar wall thickening and capillary rarefaction, the latter being
speciﬁc to uremia [29, 34].
The functional consequences of all the aforemen-
tioned structural changes include diastolic dysfunction [35],
increased oxygen demand and impaired, myocardial oxy-
genation unrelated to coronary obstruction [34, 36]. This
may explain the angiographic ﬁnding of patent coronaries
in 30%–40% of uremic patients with ischemic heart dis-
ease/angina pectoris [34], as well as their predisposition to
arrhythmias, both atrial and ventricular, and sudden death,
which account for more than half of the cardiovascular
mortality of patients on RRT [37, 38]. Susceptibility to
arrhythmias and sudden death may be further increased
by coronary artery disease/myocardial infarction, left ven-
tricular hypertrophy, congestive heart failure, electrolyte
abnormalities, chronic ﬂuid overload, anemia, autonomic
imbalance, and inﬂammation [38].4 International Journal of Nephrology
3.2. Vascular Changes in CKD. Ever since early reports
of aortic thickening in uremic patients by Richard Bright
in 1827, renal disease has been associated with vascular
pathology [39]. Pathologic features include reduced elastic-
ity/compliance of large arteries, as reﬂected in an increase of
the arterial pulse wave velocity (PWV) [40, 41], thickening
of the arterial wall, leading to an increased intima-media
thickness (IMT) [42], and, mainly, vascular calciﬁcation
[43, 44].
Vascular calciﬁcation has recently been the focus of
attention mainly because of its established association with
cardiovascular mortality in CKD patients [45]. Moreover,
in the last decade, research has shown that it is not
simply the result of passive mineral precipitation but rather
an active and highly regulated process, closely resembling
osteogenesis [43, 46], and is orchestrated by the arterial
smooth muscle cell after its genotypic transformation to an
osteoblast-like cell [43]. Ossiﬁcation of the arterial wall is
favoured by conditions like ageing, diabetes, inﬂammation,
and especially CKD. In renal disease, vascular calciﬁca-
tion is linked to hyperphosphatemia, lack of calciﬁcation
inhibitors(i.e.,fetuin-A,matrix GLaprotein,osteopontin,or
pyrophosphate) and derangemen t si nr e g u l a t o r so fm i n e r a l
metabolism(i.e., vitamin D,parathormone, osteoprotegerin,
and bone morphogenetic proteins) [43], and abnormalities
in bone turnover such as secondary hyperparathyroidism
and adynamic bone disease [46–48].
In addition, recent studies implied a role for the
phosphatonin Fibroblast Growth Factor-23 (FGF-23) in the
pathophysiology of chronic kidney disease—mineral bone
disorder (CKD-CMD) and in vascular calciﬁcation. FGF-
23 levels are elevated in CKD patients both on dialysis
and on conservative treatment and have been associated
with increased mortality and left ventricular hypertrophy.
Moreover, FGF-23 has been linked to increased arterial
stiﬀness, endothelial dysfunction, and vascular calciﬁcation.
However, a causative relation and its value as a marker of
cardiovascular status and/or phosphate-related toxicity, as
well asitspotential role asa target forintervention,still await
further clariﬁcation [49].
Calcium deposits may surround atheromatous plaques
in the arterial intima (atherosclerosis) or involve the medial
layer of the arteries (arteriosclerosis—Moenckeberg’s scle-
rosis) [50]. They can be visualised in plain X-ray ﬁlms
[51, 52] and quantiﬁed by more sophisticated and more
expensive techniques like electron beam computed tomog-
raphy (EBCT) [53, 54], the latter regarding mainly coronary
artery calciﬁcation (CAC).
Whether vascular intima and media calciﬁcation are
really distinct entities still remains controversial. Because
of the results from experimental models as well as their
diﬀerence in histopathologic features, location in the arterial
tree, and pathophysiologic consequences, they tend to be
regarded as distinct [50] although this view has recently
been challenged [55, 56]. Both types of vascular calciﬁcation
appear early in CKD, run an accelerated course, especially
after RRT initiation [53, 54], and lead to high cardiovascular
morbidity and mortality [45]. More importantly, a recent
metareview on treatments for vascular calciﬁcation in CKD
has demonstrated that no therapy to date, including statins
and sevelamer, appears to inﬂuence their rate of progression
[57].
In CKD patients, CAC score measurement as a tool
for cardiovascular risk stratiﬁcation may be aﬀected by the
unique presence of medial coronary calciﬁcation [58, 59]
unrelated to obstructive coronary atherosclerosis, thus not
necessarily leading to ischemia. Nevertheless, a high CAC
score has been associated with increased mortality in CKD
patients both before [60] and after the initiation of dialysis
[61]. Apart from medial calciﬁcation, another feature
characteristic of coronary artery disease (CAD) aﬀecting
CKD patients is the location of culprit atherosclerotic
lesions. In renal patients with acute myocardial infarction,
they were found to be located more proximal tothe coronary
ostia, which may account for the observed increased
mortality [62].
Because CAD is highly prevalent in CKD patients, non-
invasive screening tools for the prediction of asymptomatic
coronary obstruction are needed. In recent studies, cardiac
Troponin T (cTnT) has emerged as a powerful predictor of
multiple-vessel CAD in asymptomatic hemodialysis patients
[63, 64]. In addition, the acute kidney injury biomarker neu-
trophil gelatinase-associated lipocalin (NGAL) has recently
been associated with both chronic renal impairment and
cardiovascular complications and might potentially prove its
worth as a cardiovascular risk predictor in CKD [65].
Aortic calciﬁcation assessed by lateral abdominal X-ray
has also been associated with all-cause and cardiovascular
mortality in dialysis patients and has been proposed as a
simple tool for cardiovascular risk assessment and treatment
guidance [52, 66].
4.CardiovascularRiskModiﬁcationinCKD
Because of the heavy CVD burden aﬀecting CKD patients,
risk modiﬁcation is vital in an eﬀort to improve outcomes.
Still CKD patients are usually excluded from large interven-
tional trials [67] because of their expected adverse outcomes,
thus hindering the evaluation of therapeutic interventions.
Furthermore, interventions for traditional cardiovascular
risk reduction already established in the general population
have proved less eﬀective in patients with CKD [24, 68, 69].
This seems to result into a kind of “therapeutic nihilism”
[24], by denying treatment despite the presence of sound
indications,forexample,theunderutilisationofantiplatelets,
statins, β blockers, and ACE inhibitors in CKD patients with
known CAD [70]. Furthermore, CKD patients are less likely
to undergo coronary angiography, percutaneous coronary
intervention, or bypass grafting, or to receive adjuvant
treatments, such as GpIIb/IIIa inhibitors [67].
Strategies to reduce cardiovascular risk in CKD patients
should target both traditional and non-traditional, that is,
CKD-related factors. Traditional risk factors include hyper-
tension, dyslipidemia, diabetes, obesity, physical activity, and
smoking habit, while CKD-related factors refer to CKD
progression, proteinuria, anemia, inﬂammation, mineral
and bone disorder, LVH, oxidative stress, coagulopathy,International Journal of Nephrology 5
hyperactivity of the renin-angiotensin and the sympathetic
nervous system, and dialysis dose and quality [67]( Table 1).
Setting of speciﬁc treatment targets is complicated, espe-
ciallyinpatientsonRRT,byﬁndings ofreverse epidemiology
with a U-shaped curve associating mortality with blood
pressure, BMI, cholesterol, and phosphate [71], possibly
a result of the Malnutrition-Inﬂammation-Atherosclerosis
(MIA) syndrome frequently encountered in this patient
population [72, 73]. Further controversies also derive from
recent results of increased morbidity and mortality in CKD
patients associated with higher hemoglobin levels [74],
intensive blood pressure [75] and glucose control [76], dual
angiotensin II blockade [77] and suppression of parathyroid
function, and bone turnover [47, 48], which question the
safety of overaggressive intervention on speciﬁc laboratory
and clinical parameters in this patient group. Rather than
meticulously pursuing generalised targets, recent opinions
suggest a potential beneﬁt from a more individualised per-
spective, that takes into account patient-speciﬁc trends and
distinctive dynamic features of the actual clinical situation
[66, 78, 79].
Eagerly awaited is the publication of results from large
randomised studies evaluating therapeutic interventions
to lower cardiovascular morbidity and mortality in CKD
patients, such as the ongoing EVOLVE (EValuation Of
Cinacalcet HCl Therapy to Lower CardioVascular Events)
[80] and the concluded SHARP (Study in Heart And Renal
Protection). The latter, a double blind placebo-controlled
study involving almost 9500 CKD patients (a third of them
on dialysis) in 18 countries, has been able to demonstrate
a signiﬁcant reduction in cardiovascular events, such as
myocardial infarction, stroke, or need for coronary artery
revascularization, with the use ofa combinationof ezetimibe
plus simvastatin, according to most recent results presented
duringtheAmericanSocietyofNephrologyRenalWeek2010
[81].
Until further results are available, current recommen-
dation for predialysis patients suggests regular exercise,
where feasible, smoking cessation, blood pressure control to
<130/80mmHg with preference to angiotensin-II-targeted
treatment, HbA1c levels of <7.0%, Hb levels of 10–12g/dL,
LDLcholesterollevelsasforthegeneralpopulationwithhigh
cardiovascular risk, sodium intake <2.4g/day, maintenance
ofaBMI <25kg/m2, treatment ofproteinuria, and avoidance
of nephrotoxicity, aiming, apart from cardiovascular pro-
tection, at renal function preservation and slowing of CKD
progression [3, 67, 82–84].
For patients on dialysis, blood pressure of <140/
90mmHg before and <130/80mmHg after dialysis is recom-
mended.Optimal levelsofHbA1cand LDL-Cseemtobe less
clearlydeﬁned,since theymay notaccuratelyreﬂectglycemic
status [85] and atherogenic potential [86], mainly because
of the short erythrocyte lifespan [85] and the qualitative
rather than quantitative lipid abnormalities in uremia [86].
Specialconsiderationmustbetakentomineralbonedisorder
aimingatnormalphosphoruslevels,avoidinghypercalcemia,
and treating secondary hyperparathyroidism judiciously in
orderto maintain the mineral buﬀeringability ofactive bone
turnover, in order to ameliorate vascular calciﬁcation [66].
Table 1: Targets for cardiovascular risk modiﬁcation in CKD.
Traditional CKD related
Physical activity Proteinuria
Smoking CKD progression
Obesity Sympathetic nervous system
Blood pressure Renin-angiotensin system
Glycemia Left ventricular hypertrophy
Lipids Mineral bone disorder
Anaemia
Inﬂammation
Oxidative stress
Coagulopathy
Dialysis dose and quality
The latter is portrayed in recent recommendations regarding
vascular calciﬁcation screening, phosphate binder choice,
and target levels of parathormone [66, 87, 88]. Also of
importance are dialysis adequacy,quality,and hemodynamic
stability, as well as the optimization of conditions regarding
inﬂammation and dialysis-related infections [89, 90].
The treatment and prevention of arrhythmias and
sudden death remains a challenge. Apart from attention
to electrolyte disorders and avoidance of low-potassium
dialysate, whenever possible, the use of β blockers seems
beneﬁcial. ACE inhibitors and angiotensin II receptor block-
ers appear promising but have yet to prove their eﬃcacy in
prospective trials [38]. Implantation of cardiac deﬁbrillators
in dialysis patients is associated with increased risk for
bleeding and infection. Compared to patients with normal
renal function, their use for primary prevention in CKD
patients confers a reduced survival beneﬁt, possibly due to
comorbid conditions or increased deﬁbrillation thresholds.
On the other hand, implantation for secondary prevention
is underused in dialysis patients, despite a proven eﬀect in
reducing mortality [37, 38].
In summary, CKD patients carry a heavy cardiovascular
burden leading to high morbidity and mortality. This can be
attributed to the high prevalence of traditional risk factors,
such as advanced age, diabetes, and hypertension but also
derives from CKD-related morbidity, such as sympathetic
and renin-angiotensin hyperactivity, sodium retention, ﬂuid
overload, anemia, dyslipidemia, mineral-bone disorder and
inﬂammation, which lead to structural alterations of the
heartandvessels(chronicrenocardiacsyndrome).Aggressive
risk modiﬁcation, high index of suspicion for cardiovascu-
lar morbidity, proper intervention, and secondary preven-
tion are essential. Large high-quality trials involving CKD
patients are urgently needed to provide results, which could
support eﬀective treatment strategies. Until such results are
available, avoiding “therapeutic nihilism” and aiming at
established treatment targets with an individualised patient-
oriented approach appears sensible.6 International Journal of Nephrology
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